Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer - Episode 7

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

, , , , ,

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

EP. 1: Overview of Current mCRC Treatment Landscape
EP. 2: Evaluating 3L Treatment Landscape Evolution
EP. 3: Fruquintinib MoA and Toxicity Profile Overview
EP. 4: Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
EP. 5: FRESCO-2 Study Highlights
EP. 6: Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
Now Viewing
EP. 7: Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
EP. 8: Consideration for Fruquintinib Dosing and Titration
EP. 9: Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
EP. 10: Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
EP. 11: Considerations for Platinum-based Therapy
EP. 12: Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
EP. 13: Real-World Data Surrounding Sequencing Strategies for Refractory mCRC
EP. 14: Data Surrounding Treatment for MSI-high Patients from ASCO 2024
EP. 15: Unmet Needs Surrounding mCRC Treatment
EP. 16: Anticipating Key Studies and Pipeline Treatments in mCRC Landscape